Dimerix Limited Share Price

Equities

DXB

AU000000DXB7

Biotechnology & Medical Research

Market Closed - Australian S.E. 07:10:45 19/04/2024 BST 5-day change 1st Jan Change
0.29 AUD 0.00% Intraday chart for Dimerix Limited -7.94% +41.46%

Financials

Sales 2022 6.47M 4.15M 335M Sales 2023 8.98M 5.76M 466M Capitalization 24.06M 15.44M 1.25B
Net income 2022 -10M -6.42M -519M Net income 2023 -13M -8.34M -674M EV / Sales 2022 4.48 x
Net cash position 2022 9.56M 6.13M 496M Net cash position 2023 2.03M 1.31M 106M EV / Sales 2023 2.45 x
P/E ratio 2022
-3.37 x
P/E ratio 2023
-1.46 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 95.76%
More Fundamentals * Assessed data
Dynamic Chart
1 week-7.94%
Current month-3.33%
1 month-7.94%
3 months+48.72%
6 months+114.81%
Current year+41.46%
More quotes
1 week
0.28
Extreme 0.275
0.31
1 month
0.28
Extreme 0.275
0.35
Current year
0.16
Extreme 0.16
0.37
1 year
0.05
Extreme 0.052
0.37
3 years
0.05
Extreme 0.052
0.48
5 years
0.05
Extreme 0.052
0.78
10 years
0.05
Extreme 0.052
0.78
More quotes
Managers TitleAgeSince
Chief Executive Officer - 26/08/18
Director of Finance/CFO - 05/05/19
Chief Tech/Sci/R&D Officer - 22/10/23
Members of the board TitleAgeSince
Chief Executive Officer - 26/08/18
Director/Board Member - 30/04/17
Chairman - 11/01/23
More insiders
Date Price Change Volume
19/04/24 0.29 0.00% 2,213,226
18/04/24 0.29 +1.75% 1,433,489
17/04/24 0.285 -1.72% 1,869,448
16/04/24 0.29 -3.33% 3,079,409
15/04/24 0.3 -4.76% 2,352,923

Delayed Quote Australian S.E., April 19, 2024 at 07:10 am

More quotes
Dimerix Limited is an Australia-based clinical-stage biopharmaceutical company. The Company is focused on developing new therapies in areas with unmet medical needs for global markets. It is focused on developing its products, DMX-200, for Focal Segmental Glomerulosclerosis (FSGS), respiratory complications associated with COVID-19 and Diabetic Kidney Disease and is developing DMX-700 for Chronic Obstructive Pulmonary Disease (COPD). Its DMX-200 and DMX-700 are identified using its assay, Receptor Heteromer Investigation Technology (Receptor-HIT), which is a scalable and globally applicable technology platform enabling the understanding of receptor interactions to rapidly screen and identify new drug opportunities. Its products target multiple global territories, with the initial focus predominantly on the United States and European markets. It has completed two Phase 2 studies: one in FSGS and one in diabetic kidney disease. Receptor-HIT is licensed to Excellerate Bioscience.
More about the company